Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm

Beta Bionics gains FDA clearance for its Mint patch pump, revises 2026 revenue guidance lower while keeping gross margin and channel mix targets.

Rhea-AI Summary

Beta Bionics (BBNX) received FDA clearance for Mint, a reusable/disposable patch insulin pump that integrates with leading CGMs and allows iOS/Android smartphone control.

Mint’s full U.S. commercial launch is expected in Q1 2027, with manufacturing capacity anticipated at a minimum of 1.5 million disposable units in 2027. At launch, Mint is expected to be available exclusively via the pharmacy channel, with about 40% of insured U.S. lives initially able to access it, rising to at least 50% within the first year. The company also unveiled its next-generation insulin dosing algorithm, 3D Intelligence, submitted to the FDA via a 510(k) and intended to power iLet 3D and Mint 3D, with U.S. commercialization targeted by end of 2026 and Q1 2027 respectively, subject to regulatory clearance.

Full-year 2026 revenue guidance is updated to $121–$126 million, down from $131–$136 million, reflecting a potential up to $10 million Q4 2026 deferral as some new iLet users may wait for Mint. The company reiterates 2026 expectations for 37%–39% of new patient starts reimbursed through the pharmacy channel and a 58.5%–59.5% gross margin. Mint is expected to be modestly dilutive to 2027 gross margin but highly accretive to long-term margins at scale.

Positive

• FDA clearance obtained for Mint patch pump, enabling U.S. commercialization plans
• 1.5 million+ disposable Mint units targeted for manufacture in 2027
• 40%–50% of insured U.S. lives expected to have Mint pharmacy coverage within first year
• 2026 revenue still guided to $121–$126 million despite deferral impact
• 2026 gross margin reiterated at 58.5%–59.5%
• Pharmacy channel projected to be a higher share of 2027 revenue with Mint contribution

Negative

• 2026 revenue guidance cut from $131–$136 million to $121–$126 million
• Up to $10 million potential revenue deferral in Q4 2026 as users await Mint
• Mint expected to be modestly dilutive to full-year 2027 gross margin

Argus 15 min delay

-21.64% vs previous close $13.00 last price 81.4x rel. volume Open Argus

Details

Market Reaction – BBNX

$13.00 $17.00 Day Range

$584.16M Market Cap

Following this news, BBNX has declined 21.64%, reflecting a significant negative market reaction. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $13.00. Trading volume is exceptionally heavy at 81.4x the average, suggesting significant selling pressure.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The May 21 Mint update recorded a 11.4% 24-hour reaction; it established the same program’s prior co...

Analysis

The May 21 Mint update recorded a 11.4% 24-hour reaction; it established the same program’s prior commercialization milestone, making this FDA clearance a subsequent regulatory progression.

Key Figures

Mint U.S. full launch: Q1 2027 2027 manufacturing capacity: At least 1.5 million disposable units iLet 3D commercialization: End of 2026 +5 more

Mint U.S. full launch

Q1 2027

Expected full commercial launch

2027 manufacturing capacity

At least 1.5 million disposable units

Full-year 2027 capacity

iLet 3D commercialization

End of 2026

Subject to FDA clearance

Insured U.S. lives with pharmacy benefit access

Approximately 40%

Expected at Mint launch

Insured U.S. lives with pharmacy benefit access

At least 50%

Expected within the first year of full commercialization

FY2026 revenue guidance

$121 million–$126 million

Previously $131 million–$136 million

Potential Q4 2026 revenue deferral

Up to $10 million

Potential impact from users awaiting Mint

FY2026 gross margin guidance

58.5%–59.5%

Reiterated full-year guidance

Historical Context

2 past events · Latest: May 21

2 events

1. May 21

   Mint timeline update

   24h Move

   +11.4%

   Mint commercialization target moved to Q2 2027, subject to FDA clearance

2. Jul 29

   Q2 earnings results

   24h Move

   -5.9%

   Q2 sales rose 38%, while full-year revenue guidance remained $131–$136 million

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

patch pump, 510(k), continuous glucose monitors, automated insulin delivery, +1 more

5 terms

patch pump medical

"Mint, the Company’s patch pump featuring a transformative reusable"

A patch pump is a small, wearable insulin delivery device that sticks to the skin and automatically delivers measured doses of insulin throughout the day; it usually pairs with a remote controller or smartphone app so users can adjust doses without carrying a traditional pump. For investors, patch pumps matter because they target a large, growing market for diabetes care, create recurring revenue from disposable patches and supplies, and face value swings tied to regulatory approvals, reimbursement rules and adoption by patients and clinicians.

510(k) regulatory

"submitted to the FDA through a 510(k) application"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

continuous glucose monitors medical

"integrates with industry-leading continuous glucose monitors (CGM)"

A continuous glucose monitor is a small wearable device with a sensor placed just under the skin that measures blood-sugar levels around the clock and sends those readings to a display or smartphone — like a fitness tracker for glucose. Investors care because adoption and repeat purchases of sensors and supplies create steady revenue, while clinical usefulness, pricing, insurance coverage and regulatory approval determine how fast and widely the devices sell.

automated insulin delivery medical

"next-generation automated insulin delivery (AID) platforms"

A system that links a glucose sensor, an insulin pump, and control software so insulin is adjusted automatically to keep blood sugar near a target range, similar to a smart thermostat that regulates room temperature. It matters to investors because it replaces manual dosing with continuous, data-driven care, which can drive device sales, recurring subscription software services, better health outcomes, and regulatory interest—factors that affect market growth and company valuation.

ipx8 technical

"Waterproof with an IPX8 rating for up to 5 feet deep"

IPX8 is a waterproof rating that indicates a device can withstand continuous immersion in water under conditions set by the manufacturer. For investors, it signals product durability and suitability for wet or outdoor use — traits that can broaden market appeal, reduce returns or warranty costs, and affect competitive positioning much like a car advertised as all-weather-ready.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Mint features a new and innovative patch pump architecture 
• Full Mint U.S. commercialization expected to begin in Q1 2027
• Manufacturing capacity expected to produce at least 1.5 million disposable Mint units during 2027
• 3D Intelligence, the Company’s next-generation insulin dosing algorithm, has been submitted to the FDA through a 510(k) application
• Expectations to commercialize 3D Intelligence in the U.S. by the end of 2026 as iLet 3D™, and at the time of full Mint launch as Mint 3D™, subject to regulatory clearance by the FDA
• Updated full year 2026 guidance

IRVINE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced U.S. Food and Drug Administration (FDA) clearance of Mint, the Company’s patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users. Mint is expected to meaningfully expand the Company’s addressable insulin delivery market, particularly among people with diabetes seeking a patch pump form factor.

Additionally, the Company is unveiling 3D Intelligence, its anticipated next-generation insulin dosing algorithm, which has been submitted to the FDA through a 510(k) application. 3D Intelligence is designed with three algorithm experiences intended to enable a more customizable treatment approach tailored to each user’s unique insulin requirements.

Subject to regulatory clearance by the FDA, Mint 3D and iLet 3D will represent Beta Bionics’ next-generation automated insulin delivery (AID) platforms, designed to maximize user choice through optionality in hardware and algorithm experience.

“We believe that our next-generation AID platform, consisting of Mint 3D and iLet 3D, will represent a transformational advancement for people living with diabetes, subject to regulatory clearance by the FDA,” said Sean Saint, President & CEO of Beta Bionics. “Beta Bionics puts people with diabetes at the center of everything we do, and each element of Mint 3D and iLet 3D reflects that philosophy. Delivering choice is critical to the community we serve, and that is what Mint 3D and iLet 3D are intended to offer: the choice of wearing a patch pump or tubed pump along with an algorithm experience that is uniquely suited to each individual, all with a particular focus on improving affordability through our efforts to expand access for both iLet and Mint in the pharmacy channel.”

Expectations for Full Launch of Mint in the United States

The Company expects to initiate the full commercial launch of Mint in the United States in the first quarter of 2027, ahead of its previous target, and anticipates manufacturing capacity to produce at least 1.5 million total disposable units in the full year 2027. The Company believes it may be able to exceed the 1.5 million unit target by accelerating staffing, improving efficiency through additional automation, and enhancing manufacturing yield.

Mint is expected to launch exclusively through the pharmacy channel, with approximately 40% of insured U.S. lives expected to be able to purchase it using their pharmacy benefit. The Company anticipates coverage for Mint to increase to at least 50% of insured U.S. lives within the first year of full commercialization as it leverages its market access footprint.

Mint 3D Features Expected at the Time of Full Launch in the United States*

• Transformative, two-piece reusable and disposable architecture
  • Smaller compared to the industry-leading patch pump
  • Seamless disposable patch change process with no phone re-pairing required
  • Firmware-over-the-air updates
  • Limits environmental waste
  • Three days of wear time, with an additional 12-hour grace period
  • 200-unit insulin reservoir
  • Never requires recharging
  • Waterproof with an IPX8 rating for up to 5 feet deep for 60 minutes
• Comprehensive software and digital integration
  • Powered by Beta Bionics’ 3D Intelligence algorithm*
  • Compatible with industry-leading continuous glucose monitors: Dexcom G7, Dexcom G7 15 Day, and Abbott’s FreeStyle Libre 3 Plus
  • iOS and Android smartphone controlled
    
    

*Commercialization of Mint 3D is subject to regulatory clearance. The device is currently investigational and not available for sale. Actual product specifications and features may vary.

3D Intelligence Features & Expectations for Launch in the United States*

3D Intelligence represents the next generation of Beta Bionics’ fully adaptive automated insulin delivery technology. Building on the Company’s experience with iLet and its real-world use across more than 40,000 users, 3D Intelligence is designed to give people with diabetes greater choice in how their insulin delivery algorithm responds to their individual needs.

3D Intelligence is designed to offer clinicians three selectable algorithm experiences that they can choose based on each patient’s unique insulin needs.

• Original – the algorithm currently available with iLet, with proven real-world experience across more than 40,000 users.**
• Optimized – an enhanced experience that builds on the currently available algorithm and incorporates learnings from the Company’s real-world experience with iLet.
• Conservative – an alternative experience designed to provide a more measured response when correcting high glucose levels.
  
  

Clinicians will be able to select the experience that best meets each user’s individual needs. Together, these three experiences are intended to provide greater personalization while preserving the core simplicity and automation of the currently available iLet experience.

Subject to regulatory clearance by the FDA, the 3D Intelligence insulin dosing algorithm is expected to power both iLet 3D and Mint 3D. Commercialization of iLet 3D in the United States is expected by the end of 2026, and commercialization of Mint 3D in the United States is expected simultaneous with the full Mint Iaunch in the first quarter of 2027, in each case, subject to regulatory clearance by the FDA.

*Commercialization of iLet 3D and Mint 3D is subject to regulatory clearance by the FDA. The devices are currently investigational and not available for sale. Actual product features may vary.

**Minor differences in adaptation compared to previous algorithm are not anticipated to have a significant impact on outcomes.

2026 Full Year Guidance & Key Considerations for 2027

For the full year 2026, the Company estimates total revenue of approximately $121 million to $126 million (previously $131 million to $136 million), reflecting a potential revenue deferral impact of up to $10 million in the fourth quarter of 2026 as new prospective iLet users could choose to await the launch of Mint.

• During the full year 2027, the Company expects Mint to recapture any revenue lost in the fourth quarter of 2026.
  
  

For the full year 2026, the Company reiterates its expectations for 37% to 39% of new patient starts to be reimbursed through the pharmacy channel.

• For the full year 2027, the Company expects pharmacy coverage for iLet to increase year over year, while the percentage of iLet new patient starts reimbursed through the pharmacy channel is expected to decline year over year as more pharmacy-covered individuals adopt Mint.
• With the contribution from Mint, pharmacy channel revenue as a percentage of total revenue is expected to increase in 2027 relative to the prior year.
  
  

For the full year 2026, the Company reiterates its expectations for gross margin of 58.5% to 59.5%.

• The Company expects Mint to be modestly dilutive to full year 2027 gross margin, and highly accretive to the Company’s long-term gross margin profile at scale.
  
  

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Beta Bionics’ proprietary insulin dosing algorithm is the first FDA-cleared algorithm that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Beta Bionics, Inc. (the “Company”) regarding the potential clearance by the FDA, including of 3D Intelligence, and the timing thereof; the implications and potential benefits of the FDA’s clearance of Mint; the timing or certainty of full commercial launch of Mint, iLet 3D and Mint 3D in the United States and related updates; the Company’s anticipated manufacturing timeline and capacity of production of Mint at commercial launch and during 2027; the implications and potential benefits of 3D Intelligence, iLet 3D, and Mint 3D for people with diabetes; the anticipated specifications and features of 3D Intelligence and Mint 3D; the anticipated coverage for Mint at commercial launch and within the first year of commercialization; and the Company’s 2026 full year guidance and expectations for 2027 regarding estimates of revenue, including revenue deferral and revenue recapture, new patient starts reimbursed through the pharmacy channel, pharmacy channel coverage and gross margin. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties, including business, regulatory, economic and competitive risks and uncertainties about the Company, risks inherent in developing product candidates, the Company’s ability to obtain adequate financing to fund its product development and other expenses, the Company’s ability to manufacture and scale production of its products and manage its supply chain, the Company’s ability to obtain adequate reimbursement and payer coverage for its products, trends in the industry, the Company’s relationships with its existing and future collaboration partners, the legal and regulatory framework for the industry, future expenditures and the potential impacts of global macroeconomic conditions. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. Other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as updated by its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 29, 2026, and other filings that Beta Bionics may make from time to time with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com

Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com

Source: Beta Bionics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the key hardware and usability features expected for Mint 3D at full U.S. launch?

Mint 3D is expected to feature a two-piece reusable and disposable architecture, be smaller than the industry-leading patch pump, and support a seamless disposable patch change with no phone re-pairing. It is designed for three days of wear with an additional 12-hour grace period, a 200-unit insulin reservoir, and no need for recharging. The pump is planned to be waterproof with an IPX8 rating (up to 5 feet for 60 minutes) and to support firmware-over-the-air updates, which the company says can help limit environmental waste.

What is 3D Intelligence and how is it intended to personalize insulin delivery?

3D Intelligence is the company’s next-generation insulin dosing algorithm submitted to the FDA via a 510(k). It is designed to offer clinicians three selectable algorithm experiences for each patient: Original, which reflects the current iLet algorithm used by more than 40,000 users; Optimized, an enhanced version incorporating real-world learnings; and Conservative, intended to provide a more measured response to high glucose levels. These options are intended to provide greater personalization while preserving the simplicity and automation of the current iLet experience.

What are the commercialization timelines for iLet 3D and Mint 3D in the United States?

Subject to FDA regulatory clearance, the company expects to commercialize iLet 3D in the U.S. by the end of 2026. Mint 3D is expected to be commercialized in the U.S. simultaneously with the full Mint launch in the first quarter of 2027. Both devices are currently investigational, not available for sale, and actual product features may vary.

How does Beta Bionics expect pharmacy coverage and channel mix to evolve in 2026 and 2027?

For 2026, the company reiterates its expectation that 37%–39% of new patient starts will be reimbursed through the pharmacy channel. In 2027, pharmacy coverage for iLet is expected to increase year over year, but the share of iLet new patient starts via the pharmacy channel is expected to decline as more pharmacy-covered individuals adopt Mint. With Mint’s contribution, pharmacy channel revenue as a percentage of total revenue is expected to rise in 2027 relative to 2026.